AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer

AstraZeneca Plc and Merck & Co's ovarian cancer drug, Lynparza, was approved by U.S. regulators for the treatment of advanced pancreatic cancer in patients with BRCA gene mutations, the British drugmaker said on Monday.

from Reuters: Health News https://ift.tt/355yZ3S
via IFTTT